| Nov 18 |
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
|
| Nov 18 |
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
|
| Nov 18 |
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
|
| Nov 16 |
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
|
| Nov 7 |
Adicet Bio GAAP EPS of -$0.34 in-line
|
| Nov 6 |
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 5 |
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
|
| Oct 17 |
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials
|
| Oct 16 |
Adicet Bio gets FDA clearance of IND amendment for stiff person syndrome treatment
|
| Oct 16 |
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
|
